142 results
8-K
EX-2.1
RVLPQ
RVL Pharmaceuticals plc
27 Nov 23
Bankruptcy or Receivership
4:06pm
the Reorganized Debtors shall be responsible for any Professional Fees incurred after the Effective Date. The sole recourse of the Professionals with respect … any further action or order of the Bankruptcy Court or any other Entity. Neither the Debtors nor the Reorganized Debtors shall be responsible for any
8-K
EX-10.1
RVLPQ
RVL Pharmaceuticals plc
20 Oct 23
Entry into a Material Definitive Agreement
5:00pm
Financial Institution, a UK Resolution Authority.
“Responsible Financial Officer” means the chief executive officer, president, chief financial officer … hereunder that is signed by a Responsible Financial Officer of a Loan Party shall be conclusively presumed to have been authorized by all necessary corporate
8-K
EX-99.1
RVLPQ
RVL Pharmaceuticals plc
13 Oct 23
Termination of a Material Definitive Agreement
4:15pm
be responsible for any Professional Fees incurred after the Effective Date. The sole recourse of the Professionals with respect to any such fees shall … , the Claims Register shall be closed and any party responsible for making distributions shall be authorized and entitled to recognize only those Holders
8-K
RVLPQ
RVL Pharmaceuticals plc
13 Oct 23
Termination of a Material Definitive Agreement
4:15pm
://restructuring.ra.kroll.com/RVL. Interested parties who may have questions related to the Chapter 11 Cases may call the responsible claims agent
UPLOAD
RVLPQ
RVL Pharmaceuticals plc
24 Aug 23
Letter from SEC
12:00am
.
Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
that the company and its management are responsible
8-K
EX-4.2
h0np0
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-4.3
wumxya
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-4.4
ollq7f8 zdtqihid
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-10.1
90v2nbp7exfgve
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
8-K
EX-4.1
aahlkfanbj kj8pnob
18 Aug 23
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
4:06pm
424B5
a9gufq ve7yf8
17 Aug 23
Prospectus supplement for primary offering
4:05pm
UPLOAD
va92s k1cv
8 Aug 23
Letter from SEC
12:00am
CORRESP
c512z5btqae yjxnx8
27 Jul 23
Correspondence with SEC
12:00am
CORRESP
2yzwlt l4d7e9ymiwfs
25 May 23
Correspondence with SEC
12:00am
UPLOAD
rx0z32j4wx3
20 Apr 23
Letter from SEC
12:00am